Lantern Pharma Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
LTRN Nasdaq 2830 www.lanternpharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Lantern Pharma Inc.

What Could Go Wrong With Recursion Pharmaceuticals Stock? - Oct 8th, 2026 5:58 pm
Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 15th, 2026 - Oct 8th, 2026 6:00 am
Lantern Pharma secures Taiwan clearances for Phase II NSCLC study - Oct 8th, 2026 5:05 am
Lantern Pharma Receives Taiwan Approvals to Open Next Stage of Phase 2 HARMONIC™ Trial of LP-300 in Never-Smoker, EGFR-Mutant NSCLC - Oct 7th, 2026 6:31 am
Lantern Pharma Inc. Announces Closing of up to $8 Million Registered Direct Offering - Sep 30th, 2026 2:01 pm
Lantern Pharma Inc. Announces up to $8 Million Registered Direct Offering - Sep 29th, 2026 6:00 am
New to The Street Show 773 Premieres Tonight on Bloomberg Television, Featuring Glint, Sagtec Global, BioVie and SafeSpace Global - Sep 26th, 2026 8:28 am
Open-Medicine AI: Lantern Pharma to Present the Agentic AI Drug Development Market, User Needs, Development Roadmap, Platform Economics, and Benchmarks, Today at 12:30 PM ET - Sep 23rd, 2026 5:45 am
Lantern Pharma Secures USPTO Notice of Allowance for LP‑284 Treatment Patent in Aggressive B‑Cell Lymphomas - Sep 22nd, 2026 5:45 am
New to The Street Broadcasts Tonight at 6:30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace Global - Sep 19th, 2026 9:45 am
Lantern Pharma to Present Open-Medicine AI — a Multi-Agentic Platform for End-to-End Therapeutic Development — Business Model, Roadmap, and Value Proposition on September 23 - Sep 17th, 2026 6:20 am
New to The Street Broadcasts at 6:30 PM ET Across Bloomberg U.S., Latin America and MENA, Featuring Lantern Pharma (NASDAQ:LTRN), SafeSpace Global (OTCID:SSGC) and FreeCast (NASDAQ:CAST) - Sep 5th, 2026 8:50 am
Lantern Pharma (LTRN) Q2 2026 Earnings Call Transcript - Aug 21st, 2026 6:28 am
Lantern Pharma Inc (LTRN) (Q2 2026) Earnings Call Highlights: AI-Driven Pipeline Advances Amid ... - Aug 19th, 2026 7:03 pm
Lantern Pharma Inc. Q2 2026 Earnings Call Summary - Aug 14th, 2026 10:51 am
Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update - Aug 14th, 2026 5:30 am
Lantern Pharma to Report Second Quarter 2026 Operating & Financial Results on August 14th, 2026 at 9:00 a.m. ET - Aug 7th, 2026 6:00 am
Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine - Aug 3rd, 2026 5:30 am
Lantern Pharma to Advance EMA-Cleared Phase 1b/2 Trial of LP-184 (Zirdafulven) in Biomarker-Selected Advanced Bladder Cancer - Jul 28th, 2026 5:45 am
Lantern Pharma Receives USPTO Notice of Allowance for Patent Covering Biomarker-Guided Treatment with LP-184 (Zirdafulven) in Multiple Solid Tumor Cancers - Jul 23rd, 2026 6:01 am